Effect of tranexamic acid on blood loss reduction after cardiopulmonary bypass

Uozaki, Yasuhiro; Watanabe, Go; Kotou, Keiju; Ueyama, Keishi; Doi, Yoshio; Misaki, Takuro

doi:10.1007/bf02913132

Cited by 10 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nine reports described multiarm trials involving a total of 23 eligible pair wise comparisons; each of these was included in the analysis as a separate trial. One hundred and four randomized comparisons, described in 90 articles, reported data on blood loss in a format suitable for this analysis. These trials involved a total of 8030 patients; 4224 received TXA and 3806 received a placebo or no intervention.…”

Section: Resultsmentioning

confidence: 99%

Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss

Ker

Prieto‐Merino

Roberts

2013

British Journal of Surgery

254

177

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss

Ker

Prieto‐Merino

Roberts

2013

British Journal of Surgery

254

177

View full text Add to dashboard Cite

show abstract

“…TA Monitoring: six monthly CK, urinalysis, liver and renal function; annual ophthalmology check for eye pressure (risk of glaucoma) [8,19,29,31,35]. AFs have not been associated with excess thrombosis or myocardial infarction in controlled trials [61-64], but there are case reports of thrombosis in patients with hypercoagulable states treated with AFs [65,66], so it is prudent to use it cautiously if there is a family history of thrombophilia or active thromboembolic disease [35,45,65,66]. TA was reported effective long-term prophylaxis in HAE type III [67].…”

Section: Long-term Prophylaxis: See Figurementioning

confidence: 99%

2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema

Bowen¹,

Cicardi²,

Farkas³

et al. 2010

All Asth Clin Immun

482

628

View full text Add to dashboard Cite

BackgroundWe published the Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) and updated this as Hereditary angioedema: a current state-of-the-art review: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema.ObjectiveTo update the International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema (circa 2010).MethodsThe Canadian Hereditary Angioedema Network (CHAEN)/Réseau Canadien d'angioédème héréditaire (RCAH) http://www.haecanada.com and cosponsors University of Calgary and the Canadian Society of Allergy and Clinical Immunology (with an unrestricted educational grant from CSL Behring) held our third Conference May 15th to 16th, 2010 in Toronto Canada to update our consensus approach. The Consensus document was reviewed at the meeting and then circulated for review.ResultsThis manuscript is the 2010 International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema that resulted from that conference.ConclusionsConsensus approach is only an interim guide to a complex disorder such as HAE and should be replaced as soon as possible with large phase III and IV clinical trials, meta analyses, and using data base registry validation of approaches including quality of life and cost benefit analyses, followed by large head-to-head clinical trials and then evidence-based guidelines and standards for HAE disease management.

show abstract

“…Other reported side effects include myalgia, muscle weakness, elevated serum creatine phosphokinase, rhabdomyolysis, and fatigue [89,90]. Antifibrinolytic agents have not been associated with excess thrombosis or myocardial infarction in controlled trials [91][92][93][94]. Few cases of venous and arterial thrombosis, including central retinal artery/vein obstruction, were reported in patients with hypercoagulable states treated with antifibrinolytic agents [95,96].…”

Section: Antifibrinolyticsmentioning

confidence: 99%